Laddar...
Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer
The Rho-GTPase-activating protein, deleted in liver cancer-1 (DLC1), has been reported to be a tumor suppressor. However, the prognostic value of DLC1 in gastric cancer (GC) remains to be fully elucidated. Fluoropyrimidine-oxaliplatin (FP-LOHP) combination therapy has been widely used for the adjuva...
Sparad:
| I publikationen: | Mol Med Rep |
|---|---|
| Huvudupphovsmän: | , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
D.A. Spandidos
2015
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4581752/ https://ncbi.nlm.nih.gov/pubmed/26239822 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2015.4173 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|